← Back to Search

Androgen Replacement Therapy

Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis

Phase 4
Waitlist Available
Led By Omar A Raheem, MD
Research Sponsored by Tulane University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Males, age 18 years and older, with a definite diagnosis of multiple sclerosis.
Low testosterone (<300 ng/dl) on two successive blood draws before 9:00 am
Must not have
Patients with BMI ≥ 35
Patients with generalized skin disease that may affect absorption of testosterone (e.g. psoriasis) or a known skin intolerance to alcohol
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to 12 weeks
Awards & highlights
Pivotal Trial
Drug Has Already Been Approved
No Placebo-Only Group

Summary

This trial is testing a testosterone injection called Xyosted in older men with Multiple Sclerosis who have low testosterone. The goal is to see if it can improve their energy, mood, thinking skills, and overall quality of life.

Who is the study for?
This trial is for male Multiple Sclerosis patients over 18 with low testosterone levels, experiencing erectile dysfunction and libido issues. Participants must be sexually active, not in a relapse phase, able to complete various health questionnaires, and commit to the study schedule.
What is being tested?
The trial tests if XYOSTED (testosterone) injections can improve sexual function, mood, cognitive abilities, life quality, bladder control and pain in men with MS and low testosterone. It involves blood tests and assessments through questionnaires.
What are the potential side effects?
Possible side effects of XYOSTED may include skin reactions at the injection site, changes in mood or energy levels, increased red blood cell count which can lead to complications like clotting disorders.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a man over 18 with a confirmed diagnosis of multiple sclerosis.
Select...
My testosterone levels were below 300 ng/dl on two morning tests.
Select...
I am a man over 18 with a confirmed diagnosis of multiple sclerosis.
Select...
My condition is stable and not currently worsening.
Select...
I am not currently experiencing a relapse.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My BMI is 35 or higher.
Select...
I have a skin condition like psoriasis that could affect how my skin absorbs medications.
Select...
I have tested positive for HIV, HTLV1, or had a positive VDRL test.
Select...
I am currently taking Finasteride.
Select...
I am a woman or a man who does not meet certain criteria.
Select...
I have a history of pituitary gland disease.
Select...
I show signs of having Lyme disease.
Select...
I have had or currently have a lump on my testicle.
Select...
I am a male who has been on hormone treatment for a condition in the past year.
Select...
I am on blood thinners or have serious health issues including heart, lung, kidney, liver diseases, diabetes, or cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Determine the change in self-reported erectile function from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using Androgen Deficiency in the Aging Male (ADAM score).
Determine the change in self-reported erectile function from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using Male Sexual Health Questionnaire short form (MSHQ-SF).
Determine the change in self-reported erectile function from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using Sexual Health in Men (SHIM score).
Secondary study objectives
Measure the change in Multiple Sclerosis lesions, indirectly from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using the serum levels of neurofilament-light chains (NF-L).
Measure the change in cognitive function from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using the Multiple Sclerosis Neuropsychological Screening Questionnaire (MSNQ).
Measure the change in cognitive function from baseline to 12-weeks after 12 weeks of treatment with XYOSTED in males with Multiple Sclerosis with low testosterone using the Symbol Digit Modalities Test (SDMT).
+8 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment open label armExperimental Treatment1 Intervention
Open-label feasibility study to determine the effects of testosterone (Xyosted 75mg subcutaneous once per week for 3 months) on erectile function in male Multiple Sclerosis patients with low testosterone.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Testosterone replacement therapy (TRT) is the most common treatment for low testosterone. It works by supplementing the body with exogenous testosterone through gels, injections, or patches to restore normal hormone levels. This is crucial for patients as it helps alleviate symptoms such as fatigue, depression, cognitive decline, and sexual dysfunction, and supports overall health by maintaining bone density, muscle mass, mood, and sexual function.
Hormonal changes and their impact on cognition and mental health of ageing men.Androgen replacement therapy in the aging male.Increasing testosterone levels and effects on cognitive functions in elderly men and women: a review.

Find a Location

Who is running the clinical trial?

Louisiana State University Health Sciences Center in New OrleansOTHER
119 Previous Clinical Trials
42,760 Total Patients Enrolled
Tulane UniversityLead Sponsor
121 Previous Clinical Trials
239,080 Total Patients Enrolled
Antares Pharma Inc.Industry Sponsor
10 Previous Clinical Trials
1,214 Total Patients Enrolled

Media Library

XYOSTED (Androgen Replacement Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04601233 — Phase 4
Low Testosterone Research Study Groups: Treatment open label arm
Low Testosterone Clinical Trial 2023: XYOSTED Highlights & Side Effects. Trial Name: NCT04601233 — Phase 4
XYOSTED (Androgen Replacement Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04601233 — Phase 4
Low Testosterone Patient Testimony for trial: Trial Name: NCT04601233 — Phase 4
~13 spots leftby Dec 2025